Filter Results
:
(651)
Show Results For
-
All HBS Web
(651)
- People (3)
- News (51)
- Research (413)
- Events (2)
- Multimedia (3)
- Faculty Publications (300)
Show Results For
-
All HBS Web
(651)
- People (3)
- News (51)
- Research (413)
- Events (2)
- Multimedia (3)
- Faculty Publications (300)
- 2016
- Blog
Building A Culture of Health - John A. Quelch: The Marketing of Prevention
By: John A. Quelch
The US will devote 17.5% of GDP to health care this year, around $3 trillion. Yet only 3 percent of that will be spent on prevention, including both primary prevention (preventing illness in the first place) and secondary prevention (preventing sick people getting...
View Details
Keywords:
Healthcare;
Healthcare Marketing;
Prevention;
Wellbeing;
Health;
Marketing;
Health Industry;
Health Industry;
Health Industry;
Europe;
North and Central America
Quelch, John A. "The Marketing of Prevention." Building A Culture of Health - John A. Quelch (blog). May 12, 2016. http://johnquelch.org/the-marketing-of-prevention/.
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate...
View Details
Keywords:
Regulation;
Pharmaceuticals;
Healthcare;
Health Care and Treatment;
Price;
Governing Rules, Regulations, and Reforms;
Pharmaceutical Industry;
Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- October 2021 (Revised February 2022)
- Case
Hospital 57357: Aligning Performance Towards a Vision of a Cancer-Free Childhood
By: Susanna Gallani and Youssef Abdel Aal
The case follows the Children Cancer Hospital in Egypt, also known as Hospital 57357, as it goes through the roll-out of a new performance management system, which Dr. Sherif Abouel Naga, founder and CEO of the hospital, had championed. This was a critical juncture as...
View Details
Keywords:
Healthcare;
Performance Management;
Performance Incentives;
Strategic Alignment;
Health Care and Treatment;
Nonprofit Organizations;
Strategy;
Alignment;
Performance Evaluation;
Mission and Purpose;
Change Management;
Health Industry;
Egypt;
Middle East
Gallani, Susanna, and Youssef Abdel Aal. "Hospital 57357: Aligning Performance Towards a Vision of a Cancer-Free Childhood." Harvard Business School Case 122-041, October 2021. (Revised February 2022.)
- Web
Women’s health is more than female anatomy and our reproductive system—it’s about unraveling centuries of inequities due to living in a patriarchal healthcare system. - Blog: Health Supplement
rectify the impact of centuries of navigating a healthcare system that wasn’t built for us. Regardless of what we call it, moving forward, our industry needs to be mindful and inclusive as we continue to...
View Details
- May 25, 2004
- Article
Specialization and Its Discontents: The Pernicious Impact of Regulations Against Specialization and Physician Ownership on the U.S. Healthcare System
Keywords:
Health Care and Treatment;
Ownership;
Governing Rules, Regulations, and Reforms;
Health Industry;
United States
Herzlinger, Regina E. "Specialization and Its Discontents: The Pernicious Impact of Regulations Against Specialization and Physician Ownership on the U.S. Healthcare System." Circulation 109, no. 20 (May 25, 2004): 2376–2378.
- September 2013 (Revised August 2014)
- Case
Claritas Genomics
By: Robert F. Higgins and Matthew Preble
Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new...
View Details
Keywords:
Boston Children's Hospital;
Genetic Engineering;
Genetically Modified;
Genetics Diagnostics;
Health Care Industry;
Healthcare IT;
Healthcare Technology;
Healthcare Ventures;
Biomedical Research;
Patrice Milos;
Genomics;
Genomic Testing;
Life Technologies;
Health Care and Treatment;
Information Technology;
Information Management;
Genetics;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Boston;
Massachusetts;
United States
Higgins, Robert F., and Matthew Preble. "Claritas Genomics." Harvard Business School Case 814-032, September 2013. (Revised August 2014.)
- September 2022
- Case
Proactive for Her
By: Rembrand Koning and Kairavi Dey
Proactive for Her began amid the COVID-19 pandemic, in August 2020 as a digital platform to provide accessible, evidence-based, primary, preventive non-judgmental healthcare services for Indian women, who were often dissuaded from seeking help as premarital sex and...
View Details
Keywords:
Women's Health;
Healthcare;
India;
Start-up;
Telehealth;
Digital Platforms;
Health Care and Treatment;
Customer Focus and Relationships;
Business Startups;
Health Industry;
Asia;
South Asia;
India
Koning, Rembrand, and Kairavi Dey. "Proactive for Her." Harvard Business School Case 723-351, September 2022.
- October 2014 (Revised April 2023)
- Case
Gilead: Hepatitis C Access Strategy (A)
By: V. Kasturi Rangan, Vikram Rangan and David E. Bloom
Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the...
View Details
Keywords:
Healthcare;
Pharmaceuticals;
Pricing;
Access To Care;
Emerging Markets;
Health Care and Treatment;
Price;
Strategy;
Ethics;
Health Industry;
Health Industry
Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A)." Harvard Business School Case 515-025, October 2014. (Revised April 2023.)
- August 2023
- Teaching Note
Vanderbilt: Transforming an Academic Health Care Delivery System, 2020
By: Michael E. Porter, Robert S. Kaplan, Mary L. Witkowski and David N. Bernstein
Teaching Note for HBS Case No. 724-373.
View Details
- September 2014
- Article
Improving the Quality of Cancer Care in America Through Health Information Technology
By: Thomas W. Feeley, George W. Sledge, Laura Levit and Patricia A. Ganz
A recent report from the Institute of Medicine titled Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis, identifies improvement in information technology (IT) as essential to improving the quality of cancer care in America. The...
View Details
Keywords:
Information Technology;
Information Technology Industry;
Cancer Care In The U.S.;
Health;
Technology;
Health Industry;
North and Central America
Feeley, Thomas W., George W. Sledge, Laura Levit, and Patricia A. Ganz. "Improving the Quality of Cancer Care in America Through Health Information Technology." Journal of the American Medical Informatics Association 21, no. 5 (September 2014): 772–775.
- August 2023
- Case
Vanderbilt: Transforming an Academic Health Care Delivery System, 2020
By: Michael E. Porter, Robert S. Kaplan, Mary L. Witkowski and David N. Bernstein
Keywords:
Health Care;
Health Care Industry;
Academic Medicine;
Value-based Health Care;
Value-based Healthcare;
Health Care Delivery;
Service Delivery;
Transformation;
Health Care and Treatment;
Corporate Strategy;
Leadership;
Health Industry;
Tennessee;
United States
Porter, Michael E., Robert S. Kaplan, Mary L. Witkowski, and David N. Bernstein. "Vanderbilt: Transforming an Academic Health Care Delivery System, 2020." Harvard Business School Case 724-373, August 2023.
- January–February 2013
- Article
Fairness, Efficiency and Flexibility in Organ Allocation for Kidney Transplantation
By: Dimitris Bertsimas, Vivek F. Farias and Nikolaos Trichakis
We propose a scalable, data-driven method for designing national policies for the allocation of deceased donor kidneys to patients on a waiting list, in a fair and efficient way. We focus on policies that have the same form as the one currently used in the United...
View Details
Keywords:
Health Care Policy;
Healthcare;
Fairness;
Resource Allocation;
Policy;
Health Care and Treatment;
Medical Specialties;
Health Industry;
United States
Bertsimas, Dimitris, Vivek F. Farias, and Nikolaos Trichakis. "Fairness, Efficiency and Flexibility in Organ Allocation for Kidney Transplantation." Operations Research 61, no. 1 (January–February 2013): 73–87.
- December 2017
- Article
Is There a Doctor in the House? Expert Product Users, Organizational Roles, and Innovation
By: Riitta Katila, Sruthi Thatchenkery, Michael Christensen and Stefanos A. Zenios
We explore the impact on innovation that professional end-users of a product have as inventors, executives, and board members in a young firm. In contrast to prior literature, which has emphasized technology roles, we put the spotlight on the executive and governance...
View Details
Keywords:
Innovation;
User Innovation;
Healthcare;
Innovation and Management;
Entrepreneurship;
Medical Devices and Supplies Industry
Katila, Riitta, Sruthi Thatchenkery, Michael Christensen, and Stefanos A. Zenios. "Is There a Doctor in the House? Expert Product Users, Organizational Roles, and Innovation." Academy of Management Journal 60, no. 6 (December 2017): 2415–2437.
- January 2014 (Revised January 2014)
- Case
Henry Schein: Doing Well by Doing Good?
By: Rebecca Henderson, Raffaella Sadun, Aldo Sesia and Russell Eisenstat
Henry Schein Inc., a distributor of supplies to dentist, physician, and veterinary practices, had sales approaching $9 billion and employed nearly 16,000 people. The company had experienced impressive growth under the leadership of Stanley Bergman and his executive... View Details
Keywords:
Leadership Development;
Strategy Execution;
Performance Management;
Corporate Culture;
Social Responsibility;
Mergers & Acquisitions;
Joint Ventures;
Partnerships;
Health Care Industry;
Healthcare Logistics Industry;
Competitive Advantage;
Strategy;
Leadership;
Global Strategy;
Selection and Staffing;
Management Style;
Organizational Culture;
Corporate Social Responsibility and Impact;
Health Industry;
Health Industry;
China;
Europe;
United States
Henderson, Rebecca, Raffaella Sadun, Aldo Sesia, and Russell Eisenstat. "Henry Schein: Doing Well by Doing Good?" Harvard Business School Case 714-450, January 2014. (Revised January 2014.)
- January 2021 (Revised March 2021)
- Case
Serum Institute of India (SII): Racing to Save Lives During a Pandemic
By: Rohit Deshpandé, Anjali Raina and Rachna Chawla
The CEO of Serum Institute of India (SII), a $12.8 billion Indian Family business is faced with a risky choice between principles and profit. SII is the largest manufacturer of vaccines in the world and Adar Poonawalla, the CEO and son of the founder has to decide how...
View Details
Keywords:
Business Ethics;
Healthcare;
COVID-19;
Vaccines;
Family Business;
Ethics;
Health Care and Treatment;
Health Pandemics;
Leadership;
Corporate Accountability;
Fairness;
Growth and Development Strategy;
Health Industry;
India;
South Asia
Deshpandé, Rohit, Anjali Raina, and Rachna Chawla. "Serum Institute of India (SII): Racing to Save Lives During a Pandemic." Harvard Business School Case 521-028, January 2021. (Revised March 2021.)
- 2013
- Working Paper
An Empirical Study of the Spillover Effects of Workload on Patient Length of Stay
By: Jillian Berry Jaeker and Anita Tucker
We use two years of inpatient data from 243 California hospitals to quantify the relationship between hospital-level workload and patient length of stay (LOS), and its "spillover" effects across patient types. Patients are categorized as medical or surgical, and the...
View Details
Keywords:
Workload;
Processing Times;
Healthcare;
Working Conditions;
Performance Productivity;
Time Management;
Health Care and Treatment;
Health Industry;
California
Berry Jaeker, Jillian, and Anita Tucker. "An Empirical Study of the Spillover Effects of Workload on Patient Length of Stay." Harvard Business School Working Paper, No. 13-052, December 2012. (Revised July 2013.)
- February 2022 (Revised April 2022)
- Case
CVS Health: Prescription for Transformation
By: Rosabeth Moss Kanter and Tuna Cem Hayirli
In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant. The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a...
View Details
Keywords:
COVID;
Caregiving;
Healthcare;
Access;
Change;
Retail;
Health;
Health Care and Treatment;
Organizational Change and Adaptation;
Transformation;
Health Industry;
Health Industry
Kanter, Rosabeth Moss, and Tuna Cem Hayirli. "CVS Health: Prescription for Transformation." Harvard Business School Case 322-091, February 2022. (Revised April 2022.)
- September 2022
- Article
The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente
By: Alyce S. Adams, Raymond Kluender, Neale Mahoney, Jinglin Wang, Francis Wong and Wesley Yin
Most hospitals have financial assistance programs for low-income patients. We use administrative data from Kaiser Permanente to study the effects of financial assistance on health care utilization. Using a regression discontinuity design based on an income threshold...
View Details
Keywords:
Healthcare;
Utilization;
Financial Assistance;
Health Care and Treatment;
Social Issues;
Poverty;
Health Industry
Adams, Alyce S., Raymond Kluender, Neale Mahoney, Jinglin Wang, Francis Wong, and Wesley Yin. "The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente." American Economic Review: Insights 4, no. 3 (September 2022): 389–407.
- January 2014 (Revised January 2014)
- Supplement
GlaxoSmithKline in China (C)
By: John Quelch and Margaret L. Rodriguez
Keywords:
China;
Healthcare;
Pharmaceutical Sales;
Ethics;
Multinational Firms and Management;
Pharmaceutical Industry;
China
Quelch, John, and Margaret L. Rodriguez. "GlaxoSmithKline in China (C)." Harvard Business School Supplement 514-092, January 2014. (Revised January 2014.) (This case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.)
- January 2017 (Revised March 2017)
- Case
SIN Capital and the Fullerton Health IPO
By: Josh Lerner and Ann Leamon
In early 2016, David Sin, founder of the Singapore-based private equity group SIN Capital and chairman of its primary holding, Fullerton Health, was deeply involved in preparations for taking Fullerton public on the Singapore stock exchange. Three years after SIN...
View Details
Keywords:
Healthcare;
Asia;
IPO;
Financing;
Singapore;
Growth;
Health Care and Treatment;
Private Equity;
Initial Public Offering;
Financing and Loans;
Strategy;
Value Creation;
Growth and Development Strategy;
Health Industry;
Singapore
Lerner, Josh, and Ann Leamon. "SIN Capital and the Fullerton Health IPO." Harvard Business School Case 817-030, January 2017. (Revised March 2017.)